A detailed history of Ameriprise Financial Inc transactions in Insmed Inc stock. As of the latest transaction made, Ameriprise Financial Inc holds 2,580,419 shares of INSM stock, worth $182 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares
2,580,419
Previous 2,530,994 1.95%
Holding current value
$182 Million
Previous $170 Million 11.08%
% of portfolio
0.05%
Previous 0.05%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$62.0 - $79.01 $3.06 Million - $3.91 Million
49,425 Added 1.95%
2,580,419 $188 Million
Q2 2024

Aug 14, 2024

SELL
$22.0 - $69.71 $4.5 Million - $14.2 Million
-204,344 Reduced 7.47%
2,530,994 $170 Million
Q1 2024

May 15, 2024

BUY
$25.72 - $29.94 $11.6 Million - $13.6 Million
452,847 Added 19.84%
2,735,338 $74.2 Million
Q4 2023

Feb 14, 2024

BUY
$23.42 - $31.74 $9.5 Million - $12.9 Million
405,778 Added 21.62%
2,282,491 $70.7 Million
Q3 2023

Nov 14, 2023

BUY
$19.86 - $26.93 $347,728 - $471,517
17,509 Added 0.94%
1,876,713 $47.4 Million
Q2 2023

Aug 14, 2023

SELL
$16.44 - $21.1 $2.4 Million - $3.07 Million
-145,713 Reduced 7.27%
1,859,204 $39.2 Million
Q1 2023

May 15, 2023

SELL
$16.26 - $21.73 $16.2 Million - $21.6 Million
-995,384 Reduced 33.18%
2,004,917 $34.2 Million
Q4 2022

Feb 14, 2023

BUY
$16.98 - $23.15 $1.6 Million - $2.18 Million
94,095 Added 3.24%
3,000,301 $59.9 Million
Q3 2022

Nov 14, 2022

BUY
$20.88 - $28.21 $4.11 Million - $5.56 Million
197,026 Added 7.27%
2,906,206 $62.6 Million
Q2 2022

Aug 15, 2022

SELL
$17.07 - $25.71 $13.2 Million - $19.9 Million
-775,049 Reduced 22.24%
2,709,180 $53.4 Million
Q1 2022

May 16, 2022

SELL
$20.42 - $28.13 $13.8 Million - $19 Million
-674,193 Reduced 16.21%
3,484,229 $81.9 Million
Q4 2021

Feb 14, 2022

SELL
$25.89 - $33.45 $290,744 - $375,643
-11,230 Reduced 0.27%
4,158,422 $113 Million
Q3 2021

Nov 15, 2021

BUY
$22.46 - $29.47 $2.36 Million - $3.09 Million
104,881 Added 2.58%
4,169,652 $115 Million
Q2 2021

Aug 16, 2021

BUY
$24.17 - $36.01 $16.5 Million - $24.6 Million
682,954 Added 20.19%
4,064,771 $116 Million
Q1 2021

May 17, 2021

BUY
$32.28 - $44.3 $14.2 Million - $19.5 Million
440,220 Added 14.97%
3,381,817 $115 Million
Q4 2020

Feb 12, 2021

BUY
$31.45 - $40.54 $18.4 Million - $23.7 Million
583,995 Added 24.77%
2,941,597 $97.9 Million
Q3 2020

Nov 16, 2020

SELL
$26.0 - $34.5 $4.5 Million - $5.97 Million
-173,008 Reduced 6.84%
2,357,602 $75.8 Million
Q2 2020

Aug 14, 2020

BUY
$14.11 - $29.42 $6.91 Million - $14.4 Million
489,613 Added 23.99%
2,530,610 $69.7 Million
Q1 2020

May 15, 2020

SELL
$13.63 - $33.98 $3.34 Million - $8.34 Million
-245,387 Reduced 10.73%
2,040,997 $32.7 Million
Q4 2019

Feb 14, 2020

BUY
$16.12 - $24.98 $6.48 Million - $10 Million
401,696 Added 21.31%
2,286,384 $54.6 Million
Q3 2019

Nov 14, 2019

BUY
$15.49 - $25.78 $24.8 Million - $41.2 Million
1,598,117 Added 557.67%
1,884,688 $33.2 Million
Q2 2019

Aug 14, 2019

BUY
$23.0 - $32.19 $814,867 - $1.14 Million
35,429 Added 14.11%
286,571 $7.34 Million
Q1 2019

May 15, 2019

SELL
$13.91 - $31.15 $2.12 Million - $4.75 Million
-152,487 Reduced 37.78%
251,142 $7.3 Million
Q4 2018

Feb 14, 2019

BUY
$11.6 - $18.7 $369,842 - $596,212
31,883 Added 8.58%
403,629 $5.3 Million
Q3 2018

Nov 14, 2018

BUY
$18.95 - $28.08 $96,948 - $143,657
5,116 Added 1.4%
371,746 $7.52 Million
Q2 2018

Aug 14, 2018

BUY
$20.0 - $29.72 $880,840 - $1.31 Million
44,042 Added 13.65%
366,630 $8.67 Million
Q1 2018

May 15, 2018

BUY
$21.69 - $32.99 $799,102 - $1.22 Million
36,842 Added 12.89%
322,588 $7.27 Million
Q4 2017

Feb 12, 2018

SELL
$26.43 - $31.78 $337,431 - $405,735
-12,767 Reduced 4.28%
285,746 $8.91 Million
Q3 2017

Nov 07, 2017

BUY
$11.61 - $31.21 $3.47 Million - $9.32 Million
298,513
298,513 $9.32 Million

Others Institutions Holding INSM

About INSMED Inc


  • Ticker INSM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 135,476,992
  • Market Cap $9.56B
  • Description
  • Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...
More about INSM
Track This Portfolio

Track Ameriprise Financial Inc Portfolio

Follow Ameriprise Financial Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ameriprise Financial Inc with notifications on news.